23andme Holding CO 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
23andMe Holding Co. filed an amended annual report to include executive compensation and corporate governance details, confirming its delisting from Nasdaq and ongoing Chapter 11 bankruptcy proceedings.
10-K: 23andMe Faces Uncertain Future Amidst Bankruptcy, Nasdaq Delisting, and Asset Sale to Regeneron
23andMe Holding Co. has filed for Chapter 11 bankruptcy, delisted from Nasdaq, and is in the process of selling substantially all of its assets to Regeneron Pharmaceuticals, Inc. for $256 million, with a higher competing bid of $305 million from an affiliate of its co-founder.
10-K: 23andMe Holdings Reports Fiscal Year 2024 Results, Cites Market Challenges and Strategic Realignment
23andMe Holding Co. released its fiscal year 2024 results, highlighting a decrease in revenue, a significant goodwill impairment, and ongoing efforts to streamline operations and focus on strategic growth areas.